Darolutamide Extends Survival in Metastatic Prostate Cancer - NCI
Por um escritor misterioso
Descrição
Adding darolutamide (Nubeqa) to ADT and docetaxel improves survival in hormone-sensitive metastatic prostate cancer, results from the ARASENS trial show.
Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate
Frontiers Second-Generation Antiandrogens: From Discovery to
Darolutamide and Survival in Metastatic, Hormone-Sensitive
View of Darolutamide (Nubeqa) Canadian Journal of Health
Prostate Cancer Treatment (PDQ®) - NCI
FDA Expands Nubeqa Indications for Prostate Cancer - GoodRx
The Hospitalization-Related Costs of Adverse Events for Novel
Cancers, Free Full-Text
The Hospitalization-Related Costs of Adverse Events for Novel
Androgen receptor pathway inhibitors, prostate cancer, and older
Prostate cancer - The Lancet
Prostate cancer Nature Reviews Disease Primers
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival
Darolutamide: New Standard of Care in Nonmetastatic CRPC?
de
por adulto (o preço varia de acordo com o tamanho do grupo)
